Tridek-One

Tridek-One

Recherche en biotechnologie

Paris, Île-de-France 553 abonnés

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

À propos

Founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148, located at Bichat Hospital in Paris, with the support of the funds Advent France Biotechnology, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. Tridek-One has announced a 3M€ funding supported by two venture funds, Advent France Biotechnology and Advent Life Sciences (UK).

Secteur
Recherche en biotechnologie
Taille de l’entreprise
2-10 employés
Siège social
Paris, Île-de-France
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2018
Domaines
Santé, Healthcare, Immunomodulation, monoclonal antibody, vasculatis et ANCA

Lieux

Employés chez Tridek-One

Pages similaires

Parcourir les offres d’emploi

Financement

Tridek-One 2 rounds en tout

Dernier round

Série inconnue

15 979 993,00 $US

Voir plus d’informations sur Crunchbase